When Immunotherapy Enters a Cancer Treatment Plan: First Line, After Surgery or Later

The folder on the kitchen table is already thick: pathology report, scan summary, a page of blood results with small stars beside the abnormal values. Somewhere in the middle of the last appointment the oncologist said the word immunotherapy, and now the question that keeps surfacing at 2 a.m. is not what it is, but when. Is it the plan, or the backup plan? Does it come before the operation or after? And why does a neighbor with what sounds like the same cancer seem to be on something completely different?

Asking when is immunotherapy used turns out to be a better question than asking whether it works, because the answer depends on where a person actually stands. The same class of medicine can be the opening move for one patient, a follow-up after surgery for another, and a later option for a third.

This explainer walks through those positions in order, with the evidence behind each, so the next conversation with the care team starts from understanding rather than guesswork.

When is immunotherapy used? The short version before the detail

Immunotherapy describes treatments that help a person’s own immune system recognize and attack cancer cells, rather than attacking the cancer directly the way chemotherapy or radiation does. The National Cancer Institute (NCI) groups it under biological therapy because the active ingredients are proteins, cells or signals borrowed from the body’s own defenses.

Where it sits in a plan comes down to three things, and oncologists weigh them in roughly this order. The first is the cancer type, because some cancers, such as melanoma, certain lung cancers, kidney cancer and bladder cancer, have well-established immunotherapy pathways, while others rarely respond. The second is stage, meaning how far the cancer has spread. The third is a set of laboratory results on the tumor itself, called biomarkers, which are measurable features that predict whether immune-based treatment is likely to help.

Put those together and three broad timing patterns emerge. Immunotherapy can be the first treatment offered when a cancer has already spread or cannot be removed by surgery. It can be given around an operation, either before surgery to shrink a tumor or afterward to reduce the risk of the cancer returning. Or it can arrive later, once a previous treatment has stopped controlling the disease.

None of these positions is a ranking of hope. A person offered immunotherapy after chemotherapy is not on a worse plan than someone offered it first; they simply have a different cancer, a different stage or different test results. The rest of this article unpacks each position so the reasoning behind a specific recommendation becomes visible.

How immunotherapy actually works, in plain language

The immune system already deals with abnormal cells every day. T cells, a type of white blood cell, patrol the body checking the surface of other cells for signs of trouble and destroying those that look wrong. Cancer cells are the body’s own cells gone astray, so they can be hard to spot, and many tumors go further by actively switching T cells off.

One of the main off switches is a checkpoint. A checkpoint is a protein handshake between a T cell and another cell that tells the T cell to stand down; it exists so the immune system does not attack healthy tissue. Some tumors display the partner protein for this handshake, PD-L1, and use it to hide. Checkpoint inhibitors are antibody medicines that block the handshake, releasing the brake so T cells can act. The NCI explains that this is why the treatment is sometimes described as taking the foot off the brake rather than pressing an accelerator.

Other approaches work differently. Cellular therapies take a patient’s own T cells, re-engineer them in a laboratory to recognize a specific target on the cancer, and return them by infusion; CAR T-cell therapy is the best known example and is used mainly in certain blood cancers. Cytokines are natural signaling proteins that can be given to rally immune activity more generally. Therapeutic vaccines train the immune system against tumor features.

The shared mechanism explains a shared timeline. Because the medicine works through the immune system rather than on the tumor directly, responses can take longer to appear on scans than with chemotherapy, and side effects tend to be immune reactions in normal organs rather than damage to fast-dividing cells such as hair follicles.

Types of immunotherapy for cancer and where each tends to be used

The types of immunotherapy for cancer differ not only in mechanism but in the point of the treatment plan where they usually appear. Knowing which category is being discussed helps make sense of the timing.

Checkpoint inhibitors are the most widely used group and the one most patients mean when they say immunotherapy. According to the NCI, they are approved for a growing list of solid tumors and some lymphomas, and they can appear at any stage of a plan: first-line for advanced disease, around surgery for certain cancers, or later after other treatments.

CAR T-cell therapy is a one-time, highly individualized treatment for some leukemias, lymphomas and myeloma. Because the cells must be collected, modified and grown in a laboratory over a period of weeks, and because the treatment requires close inpatient monitoring, it has typically been used after standard treatments have not held the disease, though its position is shifting as evidence accumulates.

Cytokines such as interferons and interleukins were among the earliest immunotherapies. They are used less often today and mostly in specific circumstances, because newer agents tend to be better tolerated.

Monoclonal antibodies that flag cancer cells for destruction, and antibody-drug conjugates that deliver a toxic payload, sit at the border between immunotherapy and targeted therapy. Some are routine components of first-line chemotherapy combinations for lymphomas and breast cancer.

Therapeutic cancer vaccines and oncolytic viruses, which are modified viruses that infect and burst tumor cells, are used in narrower situations, often in melanoma or within clinical trials.

A person may receive more than one type over time, and the label immunotherapy on a treatment calendar always deserves the follow-up question: which kind, and why this one now?

At what stage of cancer is immunotherapy used?

Stage describes how large a cancer is and how far it has traveled, usually on a scale from stage 0 or I, meaning small and local, to stage IV, meaning spread to distant organs, which is also called metastatic. Immunotherapy has historically been most used in stage IV disease, and that remains true today, but the picture has broadened considerably.

In advanced or metastatic cancer, immunotherapy is frequently part of the first treatment offered, either alone or combined with chemotherapy, depending on the cancer type and biomarker results. This is where the evidence base is deepest, because the earliest large trials were run in people with melanoma and lung cancer that had already spread.

In earlier stages, the goal changes from controlling visible disease to lowering the chance that microscopic cells left after surgery grow back. Here immunotherapy is used as adjuvant treatment, meaning treatment given after the main operation, or neoadjuvant treatment, meaning treatment given before it. The Mayo Clinic notes that these approaches are now established for some stage II and III cancers, particularly melanoma, and are being studied in many others.

Very early cancers, such as small stage I tumors that surgery removes completely, are rarely treated with immunotherapy because the added risk of immune side effects is usually not justified when the chance of recurrence is already low.

The important nuance is that stage alone never decides the question. A stage III lung cancer with high PD-L1 and a stage III lung cancer with none may be offered quite different plans. Stage tells the team how urgent and how extensive treatment must be; the tumor’s biology tells them which tools are likely to work.

What qualifies you for immunotherapy, and who is usually asked to wait

Eligibility rests on three pillars: the cancer, the tumor’s biology and the person’s overall health.

Cancer type and stage come first, as described above. Then the pathology laboratory looks for biomarkers on a tissue sample. The most common is PD-L1 expression, reported as the proportion of tumor cells displaying the protein; higher levels often predict a better chance of response to checkpoint inhibitors, though people with low levels sometimes respond as well. Two other markers, microsatellite instability (a sign that the tumor’s DNA repair machinery is faulty) and high tumor mutational burden (a large number of genetic errors in the tumor), make a cancer look more foreign to the immune system and can qualify a person for immunotherapy regardless of where the cancer started, according to the NCI.

General fitness matters because immune side effects can be serious and the body must be able to withstand them. Oncologists use a performance status score, a simple scale of how much a person can do day to day, to guide this judgment.

Some people are usually asked to wait or offered alternatives:

• Those with active autoimmune disease such as lupus or inflammatory bowel disease, because releasing the immune brake can flare these conditions.
• Recipients of organ transplants who take medicines that suppress immunity, since immunotherapy can trigger rejection.
• People taking high-dose steroids for another reason, which can blunt the treatment’s effect.
• Anyone with a tumor showing no relevant biomarkers where evidence for benefit is weak.
• People who are pregnant, for whom safety data are lacking.

These are cautions, not absolute bans, and the treating team weighs each against the alternatives.

Immunotherapy as first-line treatment: when it is the opening move

First-line treatment is the first therapy given for a cancer at a particular stage. For a growing number of advanced cancers, immunotherapy is now a standard first-line option, and understanding why clarifies when it is chosen.

The strongest case arises when the tumor shows features that predict immune response. In non-small cell lung cancer with high PD-L1 expression and no targetable genetic mutations, guidelines endorsed by the NCI describe checkpoint inhibitors, alone or with chemotherapy, as a standard first-line approach. Melanoma that has spread is another example where immunotherapy typically leads, because this cancer is unusually visible to the immune system.

Kidney cancer, bladder cancer, some head and neck cancers, certain gastric and esophageal cancers, and any cancer with high microsatellite instability are also frequently treated with immunotherapy up front, either alone or combined with chemotherapy or a targeted drug.

Why not use it first for everyone? Three reasons. Some cancers, such as most pancreatic and prostate cancers, respond poorly regardless of timing. Some tumors carry a specific driver mutation for which a targeted pill works faster and better, so the target is treated first. And in cancers where the evidence for first-line immunotherapy is limited to trials, it remains second-line or investigational.

A practical detail people often miss: first-line immunotherapy is given with the aim of long-term control, and the treatment calendar can stretch to a year or two of infusions in advanced disease, with the interval between visits typically ranging from two to six weeks depending on the agent, as the NCI describes. The team sets the schedule; it is not a fixed length that applies to everyone.

Immunotherapy after surgery, and sometimes before it

Surgery removes what can be seen. The worry that keeps surgeons and oncologists talking after an operation is the cell that cannot be seen: a few tumor cells that escaped into the bloodstream or lymph nodes before the tumor came out. Adjuvant therapy, meaning treatment given after surgery, exists to reduce the chance those cells grow into a recurrence.

Immunotherapy has joined chemotherapy and hormone therapy as an adjuvant option for selected cancers. Melanoma that has reached the lymph nodes is the clearest example, where a year of checkpoint inhibitor treatment after surgery is an established standard described by the NCI. Some kidney, lung, bladder and esophageal cancers now have adjuvant immunotherapy pathways as well, usually restricted to people whose tumors show higher-risk features or particular biomarkers.

Neoadjuvant therapy is the mirror image: treatment given before surgery. The logic is twofold. A tumor that shrinks may be easier to remove with a smaller operation. And giving immunotherapy while the tumor is still in the body may let the immune system learn from a large supply of cancer cells, potentially producing a stronger, longer-lasting response than treatment given after the tumor is gone. This is an active area of research, and for some lung cancers and melanomas a combined approach, with treatment before and after surgery, has become an accepted option.

The trade-off is real. Adjuvant treatment is given to people who may already be free of cancer, so any side effect is borne by someone who might not have needed the medicine. Teams reserve it for cases where the recurrence risk is high enough to justify that gamble, and the decision is always shared.

Is immunotherapy a last resort? Where it fits later in the course

The phrase last resort still clings to immunotherapy because of its history. The first checkpoint inhibitors were approved for people with advanced melanoma who had exhausted other options, and CAR T-cell therapy was initially approved only after several rounds of chemotherapy had failed. Those origins shaped public perception.

The reality today is that immunotherapy is usually not a last resort, but it can still be a later-line treatment, and that is a legitimate and valuable position. Second-line treatment is the therapy given after the first has stopped working or caused unacceptable side effects. For cancers where chemotherapy remains first-line, such as many lung cancers with low PD-L1, some bladder cancers and certain lymphomas, a checkpoint inhibitor is often the standard second-line choice.

Later use also happens for practical reasons. Biomarker results may arrive after treatment has already begun. A person may have been too unwell at diagnosis to tolerate immune side effects and grown stronger after initial treatment. Or new evidence may have emerged during their course.

CAR T-cell therapy illustrates how positions shift. Once used only after multiple failed treatments in aggressive lymphoma, it is now an option earlier, after a single relapse, for some patients. The NCI describes this movement of therapies toward earlier lines as a consistent pattern once safety and benefit are established.

For someone being offered immunotherapy after chemotherapy, the useful reframing is this: the plan was sequenced, not exhausted. Ask the team what the goal of this line is and what would come next if it does not hold; a good plan has an answer.

Immunotherapy vs chemotherapy: when is one used instead of the other, and when together?

People often frame the choice as immunotherapy vs chemotherapy, but in practice the two are frequently partners rather than rivals. Understanding the logic helps explain a plan that includes both.

Chemotherapy kills cells that divide quickly, cancer cells among them. It acts within days and tends to produce measurable shrinkage on the first follow-up scan if it is going to work. Immunotherapy acts through the immune system and can take weeks to months to show an effect. Chemotherapy also causes predictable side effects such as low blood counts, nausea and hair loss that end when treatment ends; immunotherapy causes inflammatory side effects that are less predictable and can persist.

Immunotherapy is used instead of chemotherapy mainly when biomarkers strongly predict immune response, most notably high PD-L1 in lung cancer and microsatellite instability in colorectal and other cancers. In those situations, trials summarized by the NCI have shown that a checkpoint inhibitor alone is a standard option, sparing the person chemotherapy’s toxicity.

Both are used together when the tumor’s biomarker profile is intermediate or low, or when the cancer is growing quickly and the team wants a fast-acting treatment alongside one intended to build a durable response. Chemotherapy may also release tumor proteins that help the immune system recognize the cancer.

Chemotherapy is used instead of immunotherapy when the cancer type rarely responds to immune treatment, when the person has a condition that makes immune side effects dangerous, or when a targetable mutation offers a better first option.

Neither is a gentle version of the other. The choice is about biology and fit, and the treating team is the right place to have the discussion.

How the timing options compare at a glance

The table below summarizes the main positions immunotherapy occupies in a treatment plan. It is descriptive, not prescriptive; individual plans vary and the treating oncologist decides which position, if any, applies.

Position in plan	Typical situation	Main goal	Common examples
First-line, advanced disease	Cancer has spread or cannot be removed; biomarkers favorable	Control disease, prolong time before progression	Melanoma; lung cancer with high PD-L1; kidney cancer; cancers with microsatellite instability
Neoadjuvant (before surgery)	Operable but higher-risk tumor	Shrink tumor, prime immune response	Some lung cancers; melanoma; selected bladder cancers
Adjuvant (after surgery)	Tumor removed but recurrence risk high	Reduce chance of recurrence	Melanoma involving lymph nodes; some kidney and lung cancers
Second-line or later	Previous treatment stopped working or was not tolerated	Regain control, extend options	Lung cancer after chemotherapy; relapsed lymphoma (CAR T)
Maintenance	After initial response to combined treatment	Hold the response for longer	Some lung and bladder cancers

A few observations stand out. The same cancer, such as melanoma or lung cancer, appears in several rows, which is exactly the point: timing depends on stage and biology, not on the cancer name alone. Maintenance therapy, which means continuing a less intensive treatment after the main course to hold a response, is a fifth position that surprises many people and is increasingly common.

When reviewing a plan, locate it in this table and ask what would move it to a different row. That single question tends to reveal the reasoning behind the whole strategy.

What the following weeks usually look like once immunotherapy starts

Most checkpoint inhibitors are given as an intravenous infusion in an outpatient clinic, typically lasting 30 to 60 minutes, with visits repeated every two to six weeks depending on the specific agent, according to the NCI. Before each infusion, blood tests check the liver, kidneys, thyroid and blood counts, because immune side effects often show up in laboratory results before symptoms appear.

The first day is usually quieter than people expect. Infusion reactions such as chills or a rash can occur but are uncommon with most checkpoint inhibitors. Fatigue in the following days is frequent and often mild.

Immune-related side effects tend to follow a loose pattern. Skin rash and itching are often the earliest, appearing within the first few weeks. Diarrhea and colitis, meaning inflammation of the bowel, commonly emerge after the first one to two months. Thyroid and other hormone gland problems, liver inflammation and lung inflammation may appear later. The NCI notes that immune side effects can begin at any time during treatment and occasionally months after it ends, which is why symptom reporting continues after the last infusion.

Scans to assess response are typically scheduled after the first two to three months. An early scan may show a tumor that looks larger, sometimes because immune cells have flooded into it; this pseudoprogression is one reason teams often wait for a second scan before changing course.

CAR T-cell therapy follows a different arc: cell collection, a manufacturing wait of several weeks, a short course of chemotherapy to make room for the new cells, then infusion and close monitoring in or near the hospital for the first weeks.

Every timeline here is typical, not guaranteed; the care team adjusts it to the person.

What people often get wrong about when immunotherapy is used

Misconceptions about timing cause real distress, so they deserve direct correction.

Myth: being offered immunotherapy means the situation is desperate. For many cancers, it is now the first treatment given, and for others it is used after surgery in people with no detectable disease at all. Its position reflects biology and evidence, not the severity of the outlook.

Myth: it works for every cancer if you can access it. Response depends heavily on the cancer type and biomarkers. Some common cancers, including most pancreatic and prostate cancers, rarely respond, and offering immunotherapy in those settings can expose a person to side effects with little prospect of benefit.

Myth: it is natural, so it has few side effects. Releasing the immune brake can cause inflammation in the bowel, lungs, liver, skin, hormone glands, heart or nerves. The Cleveland Clinic and the NCI both describe these as potentially serious and sometimes permanent, particularly effects on the thyroid or other hormone glands.

Myth: if the first scan shows growth, it has failed. Immune responses can lag and tumors can temporarily swell with immune cells. Teams usually confirm progression on a second scan before stopping.

Myth: chemotherapy is old-fashioned and immunotherapy replaces it. The two are often combined deliberately, and for many cancers chemotherapy remains the more effective first choice.

Myth: a friend’s plan should be the same as mine. Two people with the same cancer name can have different stages, biomarkers and health backgrounds, which leads to different, equally valid plans.

The consistent thread: timing is a clinical judgment grounded in tumor biology, and it can only be interpreted in the context of one person’s results.

Questions to ask your care team about immunotherapy timing

Appointments move quickly and questions evaporate under pressure. Writing them down beforehand keeps the conversation anchored to what matters. These are the ones that tend to open up the reasoning behind a plan.

• Which type of immunotherapy are you recommending, and how does it work in my cancer?
• Where in my overall plan does it sit: first treatment, before or after surgery, or after another treatment? Why that position for me?
• Which biomarker tests were done on my tumor, and what did they show? Were any results still pending when the plan was made?
• Is the goal to control the cancer long term, to reduce the chance of recurrence, or to hold a response already achieved?
• Would chemotherapy, targeted therapy or a combination be an alternative, and what would change your recommendation?
• Do I have any health conditions that raise the risk of immune side effects, and how will we watch for them?
• How often are infusions planned, how long is the intended course, and what would lead you to stop early or continue longer?
• When is the first scan, and how will you interpret a result that looks worse before it looks better?
• Which side effects should I report the same day, and who do I call outside clinic hours?
• Is there a clinical trial relevant to my situation, and what would participating involve?
• If this treatment does not hold the cancer, what are the likely next steps?

Bringing a second person to take notes, or asking permission to record the conversation, helps. Many teams also provide a written summary of the plan; requesting one is reasonable and routine.

The aim is not to challenge the recommendation but to understand it well enough to live with it comfortably, and to recognize when something changes that would warrant a fresh discussion.

When to call your doctor during or after immunotherapy

Because immunotherapy side effects are inflammation in normal organs rather than direct cell damage, they can start subtly and worsen quickly if untreated. The single most protective habit is early reporting: teams can usually manage immune reactions well when told promptly, and delay is what turns a manageable problem into a hospital admission. The NCI stresses that this vigilance continues for months after the final infusion.

Contact the oncology team the same day, or use the emergency number they provided, for any of the following:

• Diarrhea that is new, increasing, contains blood, or comes with severe abdominal pain, which may signal colitis.
• New or worsening shortness of breath, dry cough or chest pain, which may signal inflammation of the lungs or heart.
• Yellowing of the skin or eyes, dark urine, pale stools or pain under the right ribs, which may signal liver inflammation.
• A widespread rash, blistering, peeling skin or mouth sores.
• Severe headache, extreme fatigue, dizziness on standing, confusion, or unusual thirst and frequent urination, which may signal hormone gland or blood sugar problems.
• Fever, especially with chills or feeling generally unwell.
• Muscle weakness, numbness, drooping eyelid, double vision or difficulty swallowing.
• Sudden severe joint pain or swelling.
• Eye pain, redness or changes in vision.

Seek emergency care immediately for difficulty breathing, chest pain, sudden confusion, seizure, or signs of a severe allergic reaction such as facial swelling or throat tightness.

People who have received CAR T-cell therapy have an additional early warning list from their team, including fever and any change in thinking or speech, because these can signal reactions that need urgent hospital treatment.

Carry a wallet card or phone note stating that you are receiving immunotherapy; emergency clinicians treat immune side effects differently from infections, and that information changes their first steps. Never stop or delay a dose on your own; report the symptom and let the treating team decide.

Frequently asked questions

What qualifies you for immunotherapy?

Qualification depends on the cancer type, its stage, and biomarker tests on the tumor, combined with your general fitness. Biomarkers such as PD-L1 expression, microsatellite instability and high tumor mutational burden predict a greater chance of response. Active autoimmune disease, an organ transplant or immune-suppressing medicines may lead the team to recommend caution or an alternative. The treating oncologist reviews all of these together before offering immunotherapy.

Is immunotherapy a last resort?

No. Although the earliest approvals were for people who had exhausted other options, immunotherapy is now a standard first-line treatment for several advanced cancers and is also used after surgery in people with no detectable disease. It can still be a valuable second-line or later option, but being offered it later reflects how a plan is sequenced rather than a lack of alternatives.

At what stage of cancer is immunotherapy used?

It is most widely used in stage IV or metastatic cancer, where it may be the first treatment given. It is also used in some stage II and III cancers before or after surgery to reduce recurrence risk, particularly melanoma and selected lung, kidney and bladder cancers. Very early stage I tumors that surgery removes completely are rarely treated with immunotherapy because the added risk usually outweighs the benefit.

When is immunotherapy used instead of chemotherapy?

Immunotherapy replaces chemotherapy mainly when tumor biomarkers strongly predict an immune response, such as high PD-L1 in non-small cell lung cancer or microsatellite instability in colorectal and other cancers. In those settings a checkpoint inhibitor alone is a standard option. When biomarkers are intermediate or low, or the cancer is growing quickly, the two are often combined instead.

How long does immunotherapy treatment usually last?

Courses vary widely. For advanced disease, checkpoint inhibitor infusions are commonly continued for up to one to two years if the cancer is controlled and side effects are acceptable, with visits every two to six weeks according to the National Cancer Institute. Adjuvant treatment after surgery is often planned for about a year. CAR T-cell therapy is a single infusion followed by weeks of monitoring. Your team sets and adjusts the length.

Can immunotherapy be given before surgery?

Yes. Neoadjuvant immunotherapy, meaning treatment given before an operation, is an accepted option for some lung cancers and melanomas and is being studied in many others. The aims are to shrink the tumor, sometimes allowing a smaller operation, and to expose the immune system to a large supply of cancer cells while the tumor is still present. Surgeons and oncologists decide together whether this approach suits a specific case.

What are the types of immunotherapy for cancer?

The main categories are checkpoint inhibitors, which release a brake on T cells; CAR T-cell therapy, which re-engineers a person’s own immune cells; cytokines, which are natural immune signaling proteins; monoclonal antibodies that flag cancer cells for destruction; therapeutic vaccines; and oncolytic viruses. Checkpoint inhibitors are by far the most commonly used in solid tumors, while CAR T is used mainly in certain blood cancers.

Why did my first scan look worse after starting immunotherapy?

A tumor can temporarily appear larger on an early scan because immune cells have moved into it, a phenomenon called pseudoprogression. Immune responses also take longer to develop than chemotherapy effects. For these reasons, teams usually confirm true progression on a second scan before changing treatment, unless symptoms are clearly worsening. Discuss any scan result directly with your oncologist rather than interpreting it alone.

Can someone with an autoimmune disease receive immunotherapy?

Sometimes, with caution. Because immunotherapy releases immune brakes, it can flare conditions such as rheumatoid arthritis, inflammatory bowel disease or lupus. People with well-controlled autoimmune disease are sometimes treated with closer monitoring, while those with active or severe disease may be offered alternatives. This is a shared decision between the oncologist, the specialist managing the autoimmune condition and the patient.

How long after immunotherapy ends can side effects appear?

Immune-related side effects can begin at any time during treatment and, according to the National Cancer Institute, occasionally months after the last infusion. Hormone gland effects such as thyroid changes can be permanent and are usually managed long term. This is why follow-up blood tests and symptom reporting continue after treatment finishes, and why any new symptom should be mentioned to the team even after a course has ended.

References

• Cancer Immunotherapy (MedlinePlus)
• Immunotherapy (Cleveland Clinic)

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.